NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Zai Lab Limited (NASDAQ: ZLAB)

 
ZLAB Technical Analysis
5
As on 29th May 2024 ZLAB SHARE Price closed @ 17.96 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 31.47 & Strong Sell for SHORT-TERM with Stoploss of 38.40 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

ZLABSHARE Price

Open 17.73 Change Price %
High 18.09 1 Day -0.50 -2.71
Low 17.52 1 Week -1.44 -7.42
Close 17.96 1 Month 3.54 24.55
Volume 352885 1 Year -18.10 -50.19
52 Week High 48.10 | 52 Week Low 13.72
 
NASDAQ USA Most Active Stocks
AMRS 0.14 100.00%
FFIE 0.44 -62.39%
RSLS 0.28 33.33%
AAL 11.62 -13.54%
CRKN 0.09 -18.18%
LMDX 0.02 0.00%
ASTS 9.02 69.23%
KTRA 0.27 42.11%
PONO 1.72 2.38%
NKLA 0.50 -1.96%
 
NASDAQ USA Top Gainers Stocks
IDRA 8.64 1909.30%
REDU 3.41 1075.86%
CTXRW 0.14 600.00%
NDRAW 0.03 200.00%
ASTSW 2.95 147.90%
GLSPT 33.43 138.62%
BIOC 0.07 133.33%
BCAC 22.71 125.30%
CFFEW 0.11 120.00%
JCIC 22.08 116.68%
 
NASDAQ USA Top Losers Stocks
OTIC 0.01 -91.67%
PTRAW 0.23 -89.59%
AUVI 0.05 -82.76%
ACAQ-UN 2.50 -73.49%
AXAS 0.03 -70.00%
FFIE 0.44 -62.39%
MILEW 0.06 -53.85%
LOTZW 0.01 -50.00%
GMBLW 0.01 -50.00%
FFIEW 0.03 -50.00%
 
 
ZLAB
Daily Charts
ZLAB
Intraday Charts
Whats New @
Bazaartrend
ZLAB
Free Analysis
 
ZLAB Important Levels Intraday
RESISTANCE19.06
RESISTANCE18.71
RESISTANCE18.49
RESISTANCE18.27
SUPPORT17.65
SUPPORT17.43
SUPPORT17.21
SUPPORT16.86
 
ZLAB Forecast June 2024
4th UP Forecast40.02
3rd UP Forecast32.95
2nd UP Forecast28.57
1st UP Forecast24.2
1st DOWN Forecast11.72
2nd DOWN Forecast7.35
3rd DOWN Forecast2.97
4th DOWN Forecast-4.1
 
ZLAB Weekly Forecast
4th UP Forecast27.88
3rd UP Forecast24.70
2nd UP Forecast22.73
1st UP Forecast20.77
1st DOWN Forecast15.15
2nd DOWN Forecast13.19
3rd DOWN Forecast11.22
4th DOWN Forecast8.04
 
ZLAB Forecast2024
4th UP Forecast87.97
3rd UP Forecast65.52
2nd UP Forecast51.64
1st UP Forecast37.76
1st DOWN Forecast-1.84
2nd DOWN Forecast-15.72
3rd DOWN Forecast-29.6
4th DOWN Forecast-52.05
 
 
ZLAB Other Details
Segment EQ
Market Capital 10020775936.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
ZLAB Address
ZLAB
 
ZLAB Latest News
 
Your Comments and Response on Zai Lab Limited
 
ZLAB Business Profile
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, and infectious diseases primarily in Greater China. The company's commercial products include Zejula for the treatment of breast cancer and non-small cell lung cancer; Optune, a device that delivers tumor treating fields; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other lymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; TPX-0022, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin-17; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. It has development, license, and collaboration agreements with GlaxoSmithKline; Paratek Bermuda, Ltd.; Five Prime Therapeutics, Inc.; Entasis Therapeutics Holdings, Inc.; Crescendo Biologics Ltd.; Novocure Limited; MacroGenics Inc.; Deciphera Pharmaceuticals, LLC; Incyte Corporation; Regeneron Ireland Designated Activity Company; Turning Point Therapeutics Inc; Cullinan Pearl Corp.; Takeda Pharmaceutical Company Limited; Schrödinger, Inc.; argenx BV; and Geneseeq Technology Inc. The company was incorporated in 2013 and is headquartered in Shanghai, China. Address: Jinchuang Plaza, Shanghai, China, 201210
 
2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service